Origen de la red de primer grado Monique Marelis.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands.
21
| Extinct | Miscellaneous Commercial Services | 21 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Monique Marelis a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Rochester Christian University | College/University | Doctorate Degree | |
Alantos Pharmaceuticals Holding, Inc.
Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Director/Board Member | |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member | |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Director/Board Member | |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Director/Board Member | |
Nyenrode Business Universiteit | College/University | Undergraduate Degree | |
Academic Medical Center
Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Hospital/Nursing Management | Corporate Officer/Principal | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member | |
University of Cambridge | College/University | Graduate Degree Undergraduate Degree | |
Pulmagen Therapeutics (Synergy) Ltd.
Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
University of Amsterdam | College/University | Graduate Degree Doctorate Degree Undergraduate Degree | |
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
University of Groningen | College/University | Doctorate Degree Undergraduate Degree | |
Wehkamp BV
Wehkamp BV Internet Software/ServicesTechnology Services Wehkamp BV provides retail shopping services through online. The firm operates as a home shopping company. It serves the Fashion, Living and Hardware industries. Wehkamp offers services to its customers such as ordering, pickup and delivery, returns, and pay and money matter services. The company was founded in 1952 and is headquartered in Zwolle, the Netherlands. | Internet Software/Services | Director/Board Member | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder | |
MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Chairman | |
Leids Universitair Medisch Centrum
Leids Universitair Medisch Centrum Hospital/Nursing ManagementHealth Services Leids Universitair Medisch Centrum provides medical research, patient care, training, and education. The firm offers fundamental medical and applied clinical research. The company was founded in 1996 and is headquartered in Leiden, the Netherlands. | Hospital/Nursing Management | Corporate Officer/Principal | |
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Pulmagen Therapeutics LLP
Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Pharmaceuticals: Major | Director/Board Member | |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Chief Executive Officer Director/Board Member | |
UNIQURE N.V. | Biotechnology | Director/Board Member Chairman Chief Executive Officer Founder Founder Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
Prince Claus Fund for Culture & Development
Prince Claus Fund for Culture & Development Miscellaneous Commercial ServicesCommercial Services The Prince Claus Fund for Culture & Development is an organization that supports cultural practitioners and artists through various awards, including the Prince Claus Seed Awards for emerging creatives and the Prince Claus Mentorship Awards for those further along in their careers. The organization is based in Amsterdam, Netherlands. The Dutch company also offers the Prince Claus Impact Awards to honor those whose work has made a positive contribution to their societies. | Miscellaneous Commercial Services | Director/Board Member | |
Stichting Stedelijk Museum Amsterdam
Stichting Stedelijk Museum Amsterdam Investment Trusts/Mutual FundsMiscellaneous Stichting Stedelijk Museum Amsterdam engages in the management and operation of an international art museum. It features modern and contemporary art and design. The firm houses a collection of paintings, sculptures, films, photographs, and furniture. It conducts exhibitions of interactive installations, books, and industrial design pieces. It also offers guided tours for students, families, and groups. The company was founded in 1874 and is headquartered in Amsterdam, the Netherlands. | Investment Trusts/Mutual Funds | Chairman | |
Rotterdam School of Management | College/University | Masters Business Admin Doctorate Degree | |
PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Director of Finance/CFO | |
REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member | |
Keen Venture Partners LLP
Keen Venture Partners LLP Investment ManagersFinance Keen Venture Partners LLP (Keen Venture Partners) is a venture capital firm founded in 2014 by Robert Verwaayen, Gerrit Alexander Ribbink and Bernardus Johannes Maria Verwaayen. The firm is headquartered in London. | Investment Managers | Founder | |
EclecticIQ BV
EclecticIQ BV Information Technology ServicesTechnology Services EclecticIQ BV develops cyber threat intelligence platform. The company was founded by Joep Gommers and Raymon van der Velder in 2014 and is headquartered in Amsterdam, the Netherlands. | Information Technology Services | Director/Board Member | |
Staten Biotechnology BV
Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member | |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member | |
Impella Cardiosystems AG
Impella Cardiosystems AG Medical SpecialtiesHealth Technology Impella Cardiosystems AG develops, manufactures, and markets minimally invasive cardiovascular support systems. The company is based in Aachen, Germany. The German company was founded by Thorsten Sieß. | Medical Specialties | Director/Board Member | |
Amt NV | Chairman | ||
HOOKIPA PHARMA INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
Covicept Therapeutics, Inc.
Covicept Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Covicept Therapeutics, Inc. is a newly founded company based in California, USA. Covicept Therapeutics is focused on developing drugs to treat diseases caused by a variety of RNA viruses, including SARS-CoV-2. The American company is backed by $2.30 million in seed funding and operational support from leading European VC firm Forbion. Covicept is developing PSJ-539, a small molecule that inhibits attachment, infection, and replication of SARS-CoV-2 and other RNA viruses. PSJ-539 has shown good tolerability and high potency with excellent and high biodistribution to tissues, including the lungs, in humans, allowing for relatively low daily doses. PSJ-539 also inhibits fibrosis, a property that may be valuable for patients infected with SARS-CoV-2, both short term and long-term. The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and antiviral medications. The company was founded by Sam Tsimikas, Philip Gordts, and Jeffrey Esko. Sam Tsimikas has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
Cint AB
Cint AB Packaged SoftwareTechnology Services Cint AB operates as a software company that develops technology. The firm specializes in software as a service solutions, as well as panel management products. Its OpinionHUB, is an exchange platform linking buyers, suppliers, and resellers of online sample. The company was founded by Bo Lennart Mattsson in 1998 and is headquartered in Stockholm, Sweden. | Packaged Software | Director/Board Member | |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman |
Estadísticas
Internacional
Países Bajos | 18 |
Estados Unidos | 11 |
Reino Unido | 10 |
Alemania | 5 |
Canadá | 3 |
Sectorial
Health Technology | 30 |
Consumer Services | 7 |
Commercial Services | 5 |
Finance | 4 |
Technology Services | 4 |
Operativa
Director/Board Member | 126 |
Corporate Officer/Principal | 44 |
Independent Dir/Board Member | 22 |
Chief Tech/Sci/R&D Officer | 22 |
Chief Executive Officer | 21 |
Las relaciones más conectadas
Insiders | |
---|---|
Hugo Slootweg | 34 |
Steven Holtzman | 28 |
Ferdinand Verdonck | 25 |
Joseph Feczko | 23 |
François Meyer | 20 |
Piers John Morgan | 18 |
Sander J. van Deventer | 17 |
George Morstyn | 17 |
Jörn Aldag | 15 |
Carlos R. Camozzi | 14 |
Gerrit Alexander Ribbink | 13 |
Hans Preusting | 12 |
Ronald Hans Wilmar Lorijn | 9 |
Philippe van Holle | 6 |
Harald Petry | 5 |
- Bolsa de valores
- Insiders
- Monique Marelis
- Conexiones Empresas